Shares of TapImmune Inc. (NASDAQ:MRKR) were down 5.4% on Tuesday . The company traded as low as $2.86 and last traded at $3.00, approximately 591,276 shares traded hands during mid-day trading. An increase of 38% from the average daily volume of 427,329 shares. The stock had previously closed at $3.17.
Several brokerages have issued reports on MRKR. Nomura reissued a “buy” rating and issued a $16.00 price target on shares of TapImmune in a research note on Tuesday, August 13th. Janney Montgomery Scott cut their price target on TapImmune from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Piper Jaffray Companies reduced their price objective on shares of TapImmune from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. ValuEngine upgraded shares of TapImmune from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research lowered shares of TapImmune from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. TapImmune currently has a consensus rating of “Buy” and an average price target of $10.15.
The company has a market cap of $144.93 million, a P/E ratio of -1.80 and a beta of 0.11. The stock’s 50-day moving average price is $3.64 and its 200-day moving average price is $5.35. The company has a current ratio of 15.83, a quick ratio of 15.83 and a debt-to-equity ratio of 0.01.
About TapImmune (NASDAQ:MRKR)
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Read More: What is the Consumer Price Index (CPI)?
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.